BRIGHT MINDS BIOSCIENCES INC.
DRUGDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Dec 18, 2026
12wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Drug: : 10 mg BGM0504 Administered SC
Type 2 Diabetes Mellitus (T2DM)
Drug: 5 mg BGM0504 Administered SC
Type 2 Diabetes Mellitus (T2DM)
BMB-101
Absence Epilepsy
BGM0504
Overweight or Obesity
BGM0504 Administered SC
Type 2 Diabetes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Drug: : 10 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
Drug: 5 mg BGM0504 Administered SC | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
BMB-101 | Phase 2 | Absence Epilepsy | - | - |
BGM0504 | Phase 2 | Overweight or Obesity | - | - |
BGM0504 Administered SC | Phase 2 | Type 2 Diabetes | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BRIGHT MINDS BIOSCIENCES INC.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in BRIGHT MINDS BIOSCIENCES INC.'s (DRUG) pipeline across Phase 3, Phase 2. Its lead program is Drug: : 10 mg BGM0504 Administered SC (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRIGHT MINDS BIOSCIENCES INC.'s next FDA catalyst?→
BRIGHT MINDS BIOSCIENCES INC.'s (DRUG) next tracked catalyst is a PDUFA expected December 18, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DRUG biotech catalysts?→
Add DRUG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRIGHT MINDS BIOSCIENCES INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.